Portfolio

 

Proprietary Pipeline

Preclinical phase
Clinical phase
 
Project, Mechanism
 
Disease area
 
Discovery
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Remetinostat
Topical HDAC inhibitor
Cutaneous T-cell lymphoma
MIV-711
Cathepsin K inhibitor
Osteoarthritis
Birinapant
SMAC mimetic
Solid tumors
(combo with Keytruda™)
High-grade serous carcinomas
MIV-818
Nucleotide DNA polymerase inhibitor
Hepatocellular carcinoma
MIV-323
Fusion protein inhibitor
RSV-infection

 

Partnership Pipeline

Preclinical phase
Clinical phase
 
Project
 
Disease area
 
Partner
 
Discovery
 
Preclinical
 
Phase I
 
Phase II
 
Phase III
 
Market
Olysio
(simeprevir)
Hepatitis C Janssen
JNJ-4178
AL-335+ odalasvir+ simeprevir
Hepatitis C Janssen
Xerclear Labial herpes GSK and Meda
MIV-802
Nucleotide NS5B polymerase inhibitor
Hepatitis C Trek Therapeutics

 

Page updated 20 July 2017